Skip to main content

ADVERTISEMENT

Huay-Cheem Tan, MBBS, MD

Case Report
08/01/2008
The X-Sizer® (ev3, Inc., Plymouth, Minnesota) is a novel thrombectomy device that effectively removes intracoronary thrombus. Recent studies suggest that pre-treatment with the X-Sizer before percutaneous coronary intervention (PCI) in a...
The X-Sizer® (ev3, Inc., Plymouth, Minnesota) is a novel thrombectomy device that effectively removes intracoronary thrombus. Recent studies suggest that pre-treatment with the X-Sizer before percutaneous coronary intervention (PCI) in a...
The X-Sizer® (ev3, Inc.,...
08/01/2008
Journal of Invasive Cardiology
Clinical Images
09/10/2010
ABSTRACT: This report describes an unusual etiology of acute coronary syndrome. A 48-year-old female presented with anginal chest discomfort and was found to have evidence of acute pulmonary edema requiring mechanical ventilation. She...
ABSTRACT: This report describes an unusual etiology of acute coronary syndrome. A 48-year-old female presented with anginal chest discomfort and was found to have evidence of acute pulmonary edema requiring mechanical ventilation. She...
ABSTRACT: This report...
09/10/2010
Journal of Invasive Cardiology
Original Contribution
08/01/2008
Drug-eluting stents (DES) have emerged as a novel technology in coronary revascularization. Ample evidence has shown that polymer-based DES effectively reduce in-stent restenosis and repeat revascularization after percutaneous coronary...
Drug-eluting stents (DES) have emerged as a novel technology in coronary revascularization. Ample evidence has shown that polymer-based DES effectively reduce in-stent restenosis and repeat revascularization after percutaneous coronary...
Drug-eluting stents (DES) have...
08/01/2008
Journal of Invasive Cardiology
04/15/2018
An evaluation of the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon vs 2.0 mm drug-eluting stent implantation in small-caliber vessel de novo coronary artery disease.
An evaluation of the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon vs 2.0 mm drug-eluting stent implantation in small-caliber vessel de novo coronary artery disease.
An evaluation of the 1-year...
04/15/2018
Journal of Invasive Cardiology
08/01/2008
Although primary percutaneous coronary intervention (PCI) has been proven to be superior to thrombolytic therapy for the treatment of acute ST-elevation myocardial infarction (STEMI),1–3 the latter approach is still widely practiced due to...
Although primary percutaneous coronary intervention (PCI) has been proven to be superior to thrombolytic therapy for the treatment of acute ST-elevation myocardial infarction (STEMI),1–3 the latter approach is still widely practiced due to...
Although primary percutaneous...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
Primary percutaneous transluminal coronary angioplasty (PTCA) has been consistently demonstrated to be superior to thrombolytic therapy and is currently the recommended therapy for myocardial infarction (MI).1 However, no-reflow phenomenon...
Primary percutaneous transluminal coronary angioplasty (PTCA) has been consistently demonstrated to be superior to thrombolytic therapy and is currently the recommended therapy for myocardial infarction (MI).1 However, no-reflow phenomenon...
Primary percutaneous...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
CYPHER™ (sirolimus-eluting stent, Cordis, Johnson and Johnson, Miami, Florida) and TAXUS® (polymer-based paclitaxel-eluting stent, Boston Scientific Corporation, Natick, Massachusetts) stents are the two drug-eluting stents (DES) currently...
CYPHER™ (sirolimus-eluting stent, Cordis, Johnson and Johnson, Miami, Florida) and TAXUS® (polymer-based paclitaxel-eluting stent, Boston Scientific Corporation, Natick, Massachusetts) stents are the two drug-eluting stents (DES) currently...
CYPHER™ (sirolimus-eluting...
08/01/2008
Journal of Invasive Cardiology